30
mg/dL
150
mg/dL
4
2.6
20
mg/dL
120
mg/dL
10
mg/dL
3
30
mg/dL
150
mg/dL
4
2.6
20
mg/dL
120
mg/dL
10
mg/dL
3
The Cholesterol Calculator allows you to analyze your lipid panel results and assess your cardiovascular risk profile. By entering your total cholesterol, LDL, HDL, and triglycerides from a standard blood test, this tool computes key derived values — VLDL, non-HDL cholesterol, and critical ratios — that provide a more complete picture of your heart health than any single number alone.
Cholesterol is a waxy, fat-like substance found in every cell of the body. It is essential for producing hormones, vitamin D, and digestive bile acids. The liver produces about 75% of the body's cholesterol, while the rest comes from dietary sources such as meat, dairy, and eggs. Cholesterol travels through the blood in lipoproteins — protein-wrapped packages that differ in density and function.
Low-density lipoprotein (LDL) is often called "bad" cholesterol because elevated levels lead to plaque buildup (atherosclerosis) in artery walls, increasing the risk of heart attack and stroke. High-density lipoprotein (HDL) is "good" cholesterol because it scavenges excess cholesterol from the bloodstream and arterial walls, transporting it back to the liver for disposal. Very low-density lipoprotein (VLDL) primarily carries triglycerides and is also considered atherogenic. Triglycerides are the most common type of fat in the blood, elevated by excess calories, refined carbohydrates, and alcohol.
The National Cholesterol Education Program (NCEP ATP III) and the American College of Cardiology (ACC) use LDL thresholds as primary targets: LDL below 100 mg/dL is optimal, 100–129 is near-optimal, 130–159 is borderline high, 160–189 is high, and 190+ is very high. Total cholesterol below 200 mg/dL is desirable, 200–239 is borderline, and 240+ is high.
However, ratios often outperform single values as cardiovascular risk predictors. The total cholesterol to HDL ratio (ideally below 5:1, optimally 3.5:1) and the LDL to HDL ratio (ideally below 3.5:1) are used by clinicians to gauge the net atherogenic burden. Non-HDL cholesterol (total minus HDL) captures all atherogenic particles including LDL and VLDL, and is considered by many guidelines to be a superior predictor than LDL alone, especially in people with high triglycerides.
VLDL is estimated using the Friedewald-derived approximation: VLDL ≈ Triglycerides / 5 (mg/dL). This is accurate when triglycerides are below 400 mg/dL. Use this calculator alongside your physician's interpretation of your full cardiovascular risk profile.
VLDL = Triglycerides / 5 (Friedewald approximation, valid when TG < 400 mg/dL). Non-HDL = Total Cholesterol − HDL. Total/HDL Ratio = Total Cholesterol / HDL. LDL/HDL Ratio = LDL / HDL. Risk category: 1 = Optimal (LDL < 130 and Total < 200), 2 = Borderline (LDL 130–189 or Total 200–239), 3 = High Risk (LDL ≥ 190 or Total ≥ 240).
Total/HDL ratio below 3.5 is optimal, below 5 is acceptable, above 5 indicates elevated risk. LDL/HDL ratio below 2 is optimal, below 3.5 is acceptable, above 3.5 is concerning. Non-HDL cholesterol below 130 mg/dL is optimal. Risk category 1 = Optimal, 2 = Borderline, 3 = High risk — consult your physician.
Inputs
Results
Total/HDL ratio of 3.08 and LDL/HDL of 1.75 are both optimal. VLDL = 100/5 = 20 mg/dL. Non-HDL = 185 − 60 = 125 mg/dL, well within the optimal range.
Inputs
Results
VLDL = 260/5 = 52 mg/dL. Non-HDL = 255 − 38 = 217 mg/dL (high). Total/HDL = 6.71 (elevated risk). LDL/HDL = 4.34 (high risk). Medical consultation and lifestyle/pharmacological intervention warranted.
LDL (low-density lipoprotein) deposits cholesterol in artery walls, contributing to plaque and atherosclerosis. HDL (high-density lipoprotein) removes cholesterol from arteries and returns it to the liver. High LDL is harmful; high HDL is protective.
Adults should have a fasting lipid panel every 4–6 years starting at age 20, or more frequently if they have risk factors such as family history, hypertension, diabetes, obesity, or smoking. People on cholesterol-lowering medications are monitored more regularly.
Diet changes can reduce LDL by 10–30%. Reducing saturated fat (replacing with unsaturated fats), eliminating trans fats, increasing soluble fiber (oats, beans, psyllium), and adding plant sterols can meaningfully lower LDL. However, genetics plays a large role — some people have familial hypercholesterolemia and require medication regardless of diet.
Non-HDL cholesterol includes LDL plus VLDL and IDL — all atherogenic particles. It is calculated as Total − HDL. Many guidelines now prefer non-HDL as a risk marker because it captures a broader range of harmful lipoproteins, especially in people with elevated triglycerides where LDL estimates may be inaccurate.
High triglycerides are caused by excess calorie intake (especially from sugar and refined carbs), alcohol consumption, obesity, poorly controlled diabetes, hypothyroidism, kidney disease, and certain medications. Reducing sugar, refined carbohydrates, and alcohol can significantly lower triglycerides.
Many researchers consider cholesterol ratios to be better cardiovascular risk predictors than LDL in isolation. A large meta-analysis in The Lancet (2007) found that the total/HDL ratio was among the strongest lipid-based predictors of cardiovascular events, outperforming LDL alone in some analyses.
VLDL (very low-density lipoprotein) primarily carries triglycerides and is atherogenic. It cannot be directly measured in a standard lipid panel; instead, it is estimated using the Friedewald formula: VLDL = Triglycerides / 5 (mg/dL). This approximation is valid when triglycerides are below 400 mg/dL.
HDL above 60 mg/dL is considered cardioprotective and is a negative risk factor (reduces overall risk). HDL below 40 mg/dL (men) or 50 mg/dL (women) is considered low and is an independent cardiovascular risk factor. Exercise, smoking cessation, and moderate alcohol consumption can raise HDL.
Traditionally, a 9–12 hour fast is recommended before a lipid panel because triglycerides are significantly affected by recent food intake. However, non-fasting total cholesterol, HDL, and LDL (calculated) are now accepted by some guidelines for initial screening, with fasting tests reserved for follow-up evaluation.
Statins (atorvastatin, rosuvastatin) are first-line therapy and can reduce LDL by 30–60%. Other options include ezetimibe (reduces intestinal absorption), PCSK9 inhibitors (very potent LDL reducers), bile acid sequestrants, and niacin. The choice depends on cardiovascular risk, LDL level, and patient tolerability.
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
Be the first to rate!
